Site search
3042 results for '' found
A Phase 3 study to investigate velzatinib [IDRX-42] compared with imatinib in adult participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors [GIST] (NCT072
A Phase 3 study to investigate velzatinib [IDRX-42] compared with imatinib in adult participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors [GIST] (NCT072
/
Generating new evidence to REduce major COMplications to iMprove the safety and efficacy of Extracorporeal membrane oxygenatioN [ECMO] in severe cardiac and respiratory failure Platform Trial [RECOMME
Generating new evidence to REduce major COMplications to iMprove the safety and efficacy of Extracorporeal membrane oxygenatioN [ECMO] in severe cardiac and respiratory failure Platform Trial [RECOMME
/
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel [BMS-986393], a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma [QUINTESSENTI
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel [BMS-986393], a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma [QUINTESSENTI
/
Pulmonary Artery Catheters in Adults Undergoing Cardiac Surgery [PUMA]: an International, Multicentre, Bayesian, Non-Inferiority Randomised Trial (NCT07612683)
Pulmonary Artery Catheters in Adults Undergoing Cardiac Surgery [PUMA]: an International, Multicentre, Bayesian, Non-Inferiority Randomised Trial (NCT07612683)
/
A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies (NCT07249905)
A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies (NCT07249905)
/
A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF RONDECABTAGENE AUTOLEUCEL, AN AUTOLOGOUS, DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE, VERSUS INVESTIGATOR’S CHOICE OF CD19 CAR T-CELL THERAPY IN PAT
A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF RONDECABTAGENE AUTOLEUCEL, AN AUTOLOGOUS, DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE, VERSUS INVESTIGATOR’S CHOICE OF CD19 CAR T-CELL THERAPY IN PAT
/
Effect of Intense Pulsed Light (IPL) on Vascularity and Hypertrophic Scar Development in Burn Donor Sites: A Randomised Controlled Trial Using Objective Imaging with the Antera 3D System
Effect of Intense Pulsed Light (IPL) on Vascularity and Hypertrophic Scar Development in Burn Donor Sites: A Randomised Controlled Trial Using Objective Imaging with the Antera 3D System
/
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk
/
A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants with Selected Advanced/
A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants with Selected Advanced/
/
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults [18 to
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults [18 to
/